Featured Content

Thomas, Marsland, MD
Vice President Integrated Community Oncology Network Former Community Representative ASCO Board of Directors

The Slow, Steady Battle To Fix Cancer Care

(Forbes) Apr 1, 2015 - After a cancer patient's first 30 days in the American medical system, the bills start stacking up—right next to the pile of paperwork explaining benefits. "It's very hard for patients to match these things up," says Dr. Thomas W. Feeley, who recently joined the Harvard Business School faculty as a senior fellow to study health-care reform.

Commentary: I believe the operative word in this is "slow." There are many new models being proposed to address the problems...



OBR Daily   Our free daily oncology focused e-news service.
Subscribe»  |  Search Archives»

Today's News

AZ Seals Immuno-Oncology Deals as Q1 Sales, Earnings, Slip

(PharmaTimes [UK]) Apr 24, 2015 - AstraZeneca has further singled out immuno-oncology as a central vein of its future business with three separate deals seeking to develop new therapies in the field.
read article »

POMALYST (pomalidomide) Label Update Including Progression-Free and Overall Survival Benefits Approved by U.S. FDA

(TheStreet) Apr 23, 2015 - Celgene Corporation today announced it has fulfilled the accelerated approval requirements for POMALYST ® (pomalidomide) based on results from MM-003, an international phase III study of POMALYST plus low-dose dexamethasone versus high-dose dexamethasone in relapsed/refractory multiple myeloma patients.
read article »

Bristol-Myers Squibb Receives Positive CHMP Opinion in the European Union for Opdivo (nivolumab) for the Treatment of Advanced Melanoma in Both First-Line and Previously Treated Patients

(Bristol-Myers) Apr 24, 2015 - Bristol-Myers Squibb Company today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending that Opdivo (nivolumab), a PD-1 immune checkpoint inhibitor, be granted approval for use in both first-line and previously treated patients with advanced (unresectable or metastatic) melanoma.
read corporate press release »

 

View ALL News »




News Story Commentary By Academic and Community Oncologists



Large Variation in Payments Seen in Oncology Practice (Medscape Medical News)

The wide variation in drug reimbursements has mostly to do with contractual terms between a given payer and a given...posted by: Robert D. Orzechowski, MBA, SPHR, SHRM-SCP

CMS Issues Guidance on Biosimilar Reimbursement and Formulary Policy (ASH)

The first affirmation that CMS is taking a close interest in biosimilars pricing and countering incentives to stay...posted by: Dean Gesme MD

The Slow, Steady Battle To Fix Cancer Care (Forbes)

I believe the operative word in this is "slow." There are many new models being proposed to address the problems...posted by: Thomas, Marsland, MD

Medicare Is Stingy In First Year Of Doctor Bonuses (Kaiser Health News)

This report confirms what we all suspected. Little return for significant increase in work. No wonder participation...posted by: Thomas, Marsland, MD

Circulating Tumor DNA in Blood Can Predict Recurrence of the Most Common Type of Lymphoma (NCI)

As we move into the era of personalized medicine, I see the circulating tumor cell assays as the next platform...posted by: Winston Wong, PharmD






OBR Training


Learn more about the OBR training platform, developed to provide an in-depth understanding of the unique business dynamics of today's oncology landscape.




OBR Job Board

Bayer has posted 8 new jobs.

Check out the OBR Job Board here.





The most comprehensive and up-to-date oncology pipeline information on the web!
OBR Pipeline Online™






View company profiles, indexes, and streaming stock quotes of over 200 oncology focused companies.

Winners/Losers

Symbol  %Δ
CVM +16.85%
AGEN +11.77%
ENZN +11.69%
TLOG -10.58%
SNTA -9.43%
HTBX -9.34%


    


OBR Radar

View upcoming pivotal oncology events such as PDUFA dates, ODAC dates, and announcement of phase III clinical trial results


Date: Q2 2015
Company: Exelixis
Product: cabozantinib

Date: August 11, 2015
Company: Roche / Genentech & Exelixis
Product: cobimetinib

Date: Q3 2015
Company: AstraZeneca PLC
Product: Iressa® (gefitinib)

See All OBR Radar items»